(Q36045315)

11 August 2017

1 reference

title

Translating therapies for Huntington's disease from genetic animal models to clinical trials (English)

1 reference

11 August 2017

0 references

2

Robert J Ferrante

1 reference

11 August 2017

1

Steven M Hersch

1 reference

11 August 2017

1 July 2004

1 reference

11 August 2017

1 reference

11 August 2017

1

1 reference

11 August 2017

3

1 reference

11 August 2017

298-306

1 reference

Standardization and statistical approaches to therapeutic trials in the R6/2 mouse

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534928

Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534928

Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534928

Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534928

Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534928

Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534928

SHIRPA, a protocol for behavioral assessment: validation for longitudinal study of neurological dysfunction in mice.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534928

The revised CONSORT statement for reporting randomized trials: explanation and elaboration

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534928

Neurological abnormalities in a knock-in mouse model of Huntington's disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534928

Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534928

Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534928

Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534928

A Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534928

Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534928

Use of SHIRPA and discriminant analysis to characterise marked differences in the behavioural phenotype of six inbred mouse strains

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534928

Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin

27 July 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.3.298

Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.3.298

Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.3.298

Lipoic acid improves survival in transgenic mouse models of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.3.298

Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.3.298

Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.3.298

Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.3.298

Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.3.298

Early phenotypes that presage late-onset neurodegenerative disease allow testing of modifiers in Hdh CAG knock-in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.3.298

Environmental enrichment slows disease progression in R6/2 Huntington's disease mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.3.298

A framework for designing transgenic crops--science, safety and citizen's concerns.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.3.298

A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.3.298

Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.3.298

'Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.3.298

Minocycline and doxycycline are not beneficial in a model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.3.298

Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.3.298

Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.3.298

Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease Mice

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534928

Therapeutic effects of cystamine in a murine model of Huntington's disease.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534928

Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534928

A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534928

Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534928

23 September 2018

Identifiers

DOI

10.1602/NEURORX.1.3.298

1 reference

11 August 2017

1 reference

11 August 2017

1 reference

PMCID

534928